Natural killer (NK) cells are immune effector cells that recognize both virally infected and malignant target cells. Unlike T and B cells, NK cells, do not belong to the adaptive immune system, and their activation and cytotoxicity is regulated via a series of non-rearranged cell surface receptors. These receptors transmit either activating or inhibitory signals, the summation of which is thought to dictate whether NK cell activation occurs or not. Functionally NK cells are able to kill target cells without prior sensitization and release potent pro-inflammatory cytokines such as interferon (IFN) and tumor necrosis factor (TNF). Discrete NK cell subsets can be identified in peripheral blood on the basis of CD56 and CD16 staining (reviewed by Cooper et al. 1 ). CD56 bright CD16 À/ þ cells are more potent producers of IFN-g in response to monokine stimulation and reciprocally interact with dendritic cells, leading to the activation of both cell types, whereas CD56 dim CD16 þ NK cells show higher cytotoxicity against malignant targets. By definition, NK cells lack the expression of CD3 and the T-cell receptor. CD3
þ CD56 þ cells are present in the peripheral blood (PB) and as these cells belong to the T-cell lineage, they share phenotypic and functional properties with NK cells. 2 When studying NK cells the interference of these NK-like T cells should be excluded.
One of the main mechanisms of target cell killing is through the granule release pathway. Following target cell conjugation and NK activation, cytotoxic granules move toward the cell surface, fuse with the cell membrane and the granule contents (including perforin and granzymes) are expelled into the synaptic junction between the effector and target cells. Until recently, it has not been possible to identify individual effector cells that have extruded their granule contents. However, recent studies show that specific membrane proteins, such as CD107a (lysosome-associated membrane protein 1, LAMP-1) are located within the cytotoxic granule membrane and are transiently expressed on the cell surface following degranulation. Monoclonal antibody (mAb) against CD107a identifies cells that have recently released their granule contents. 3 Penack et al. 4 have used CD107a to investigate NK cell subsets responsible for target cell cytolysis. They report that following co-culture with tumor targets, a CD56 dim CD16 À NK cell subset underwent de-granulation as these cells expressed CD107a. They concluded that this NK cell subpopulation was exclusively responsible for target cell cytotoxicity given that other NK cell subsets (CD56 þ cells downregulate CD16 upon interaction with target cells (Figure 2a vs b, left) .
In order to confirm that the CD56 dim CD16 þ population is the source of cells with reduced CD16 staining after target encounter, purified CD56 þ CD16 þ cells were cultured either with or without K562 cells in the presence of a CD107a-specific mAb as described above. In the absence of targets, these cells did not express CD107a (Figure 3a , left) and retained their phenotype (Figure 3a, middle) . In contrast, after 4 h of co-culture with K562, a proportion of cells showed CD107a staining (Figure 3b, left) and there was a continuous reduction in CD16 staining intensity, giving rise to NK cells with dim CD16 staining and an emergence of CD56 þ CD16 À cells (Figure 3b, middle) . Thus, upon co-culture with K562 cells, some CD56 dim CD16 þ cells gained CD107a on the cell surface and downregulated CD16 expression (i.e., became CD56 þ CD16 dim or even CD56 þ CD16 À ). Both events (granule exocytosis and loss of CD16) are dependent upon the presence of target cells. However the two phenotypic changes -gain of CD107a and loss of CD16 -do not necessarily coexist at a single-cell level (Figure 3b, right) as not all cells loosing CD16 were CD107a þ and conversely CD107a could be expressed by cells that did not downregulate CD16, suggesting that these two events are not completely linked.
Previous studies demonstrated that following NK cell stimulation, CD16 shedding occurs through the activation of matrix matalloproteases (MMPs). 6 As it was possible that target cell engagement leads to a similar sequence of events, we investigated the role of MMPs in target-cell induced CD16 downregulation. CD56 þ CD16 þ NK cells were incubated with K562 targets in the presence of increasing concentrations of a Letters to the Editor broad-spectrum MMP inhibitor, GM6001 (Gallardin, Calbiochem, San Diego, USA). GM6001 inhibited CD16 shedding induced by target cells in a dose-dependent manner (Figure 4a , bottom panels). The MMP inhibitor did not affect the phenotype of NK cells incubated in the absence of targets (Figure 4a upper panels). This result shows that MMP activation, resulting from co-incubation with target cells, is responsible for the observed CD16 downregulation. Inhibition of MMPs prevented CD16 loss, however, it did not reduce degranulation (as measured by CD107a staining, Figure 4b ), allowing us to dissociate the two phenotypic changes induced by targets.
PMA induced shedding of CD16 by NK cells is not dependent on tyrosine protein kinases nor protein kinase C, 7 which are major downstream pathways of NK cell activation. Co-incubation of NK cells with K562 targets induces release of cytotoxic granule contents (as evidenced by CD107a staining, Figures 2-4 ) and granule release likely involves protein kinase activation. Our data shows that target-cell induced CD16 shedding occurs via MMP activation yet, this MMP activation is neither unique to de-granulating NK cells (Figure 4b , bottom left) nor is it necessary for degranulation ( Figure 4b, bottom right) .
We also find that in addition to CD56 
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